BCR 5'RACE Full-Length Sequencing

BCR 5'RACE Full-Length Sequencing

1. Background

The B cell receptor (BCR) and its secreted antibody form are composed of an immunoglobulin heavy chain (IgH) and a light chain (Igκ/Igλ). Through four mechanisms—V(D)J gene recombination, junctional nucleotide insertions and deletions, somatic hypermutation (SHM), and class switch recombination (CSR)—they generate near-infinite diversity, forming the molecular basis by which humoral immunity recognizes antigens, achieves antibody affinity maturation, and establishes immune memory. The full-length variable-region sequence carries all of the information that defines antibody specificity and, in combination with the constant region, enables resolution of antibody isotypes (IgM/IgG/IgA/IgD/IgE), SHM levels, and clonal lineage evolution. It is therefore an indispensable data foundation for antibody drug discovery, vaccine immunogenicity assessment, and B-cell malignancy research.

The RNA-based 5'RACE technology employs SMART template switching to introduce a universal adapter at the 5' end of the cDNA, enabling a single primer pair to amplify the full-length variable region across all IGHV/IGKV/IGLV gene families and avoiding the amplification bias arising from primer-efficiency differences in multiplex PCR. In combination with a 12-nt UMI, it enables PCR-duplicate removal and sequencing-error correction, bringing clonal-abundance quantification closer to true molecular counts. At the same time, preservation of constant-region information makes antibody isotype identification and class-switch analysis possible, while full-length coverage provides the complete sequence basis for precise SHM localization and clonal lineage tree construction.

At the regulatory and industry level, the FDA's Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment (2020) confirms that NGS-based immunoglobulin rearrangement detection can be used for MRD assessment; the FDA-cleared clonoSEQ assay (De Novo, DEN170080), built on the principle of NGS-based immune receptor rearrangement, has been incorporated into NCCN guidelines for multiple myeloma, B-ALL, and CLL; and, building on the BIOMED-2 primer system, the EuroClonality-NGS consortium has established a standardized protocol for NGS-based IG rearrangement analysis. The FDA's Considerations for the Development of CAR T Cell Products (2024) and Long-Term Follow-Up After Administration of Human Gene Therapy Products (2020) set explicit requirements regarding the clonal composition and long-term follow-up of B-cell–targeting CAR-T and similar products. The RNA-based full-length + isotype + UMI approach provides high-resolution, reproducible clonotype data to support antibody drug development as well as vaccine and humoral immunity research.

ZhuHai GeneRulor offers an end-to-end service spanning sample QC, cDNA synthesis and library construction, high-throughput sequencing, and systematic immune repertoire and antibody-feature bioinformatics, helping customers precisely characterize BCR clonal dynamics, antibody isotype distribution, and SHM evolution trajectories at full-length resolution.

2. Technical Principle

This service is based on SMART template switching and the 5'RACE strategy. Starting from total RNA, full-length BCR V(D)J sequences are enriched by semi-nested PCR, with a 12-nt UMI introduced early in library construction to enable single-molecule quantification. The core steps are as follows:

（1）RNA Input and Reverse Transcription

Using high-quality total RNA (RIN ≥ 7) as the template, oligo-dT-primed reverse transcription synthesizes first-strand cDNA, capturing poly(A)-tailed immunoglobulin transcripts.

（2）SMART Template Switching and UMI Incorporation

Template switching occurs at the 5' end of the cDNA during reverse transcription, introducing a universal adapter sequence containing a 12-nt UMI. Each original mRNA molecule thereby acquires a unique molecular tag, laying the foundation for downstream deduplication and error correction.

（3）Semi-nested PCR Enrichment and Isotype Discrimination

PCR1 performs selective amplification using the universal 5' adapter together with immunoglobulin constant-region–specific primers (IgM/IgG/IgA/IgD/IgE/Igκ/Igλ); the design of the constant-region primers simultaneously enables isotype and class-switch analysis. PCR2 adds dual-index (UDI) sample barcodes and Illumina sequencing adapters at both ends.

（4）High-throughput Sequencing and Data Analysis

Illumina 2×300 bp paired-end sequencing covers the full-length V(D)J. Following UMI deduplication, error correction, and IMGT/MiXCR alignment, IgH/Igκ/Igλ clonotype reconstruction, isotype distribution, SHM localization, and clonal lineage tree construction are completed (see Section 5).

Figure 1. Workflow of BCR 5'RACE Full-Length Sequencing

3. Technical Features and Advantages

（1）Unbiased Full-length Amplification

A single primer pair covers all IGHV/IGKV/IGLV gene families, fundamentally eliminating the primer bias inherent to multiplex PCR. It fully covers all variable regions (FR1–FR4 + CDR1–CDR3), providing the complete sequence basis for precise SHM localization, clonal lineage analysis, and candidate antibody sequence mining.

（2）Antibody Isotype and Class-Switch Resolution

Using constant-region–specific primers, the five heavy-chain isotypes (IgM/IgG/IgA/IgD/IgE) are simultaneously distinguished, with quantitative analysis of isotype distribution and class-switch recombination dynamics—providing key data for staging the humoral immune response and assessing vaccine immunogenicity.

（3）SHM and Clonal Lineage Analysis

Full-length variable-region coverage supports precise calculation of the somatic hypermutation rate, mutation-site localization, and resolution of affinity-maturation trajectories. Clonal lineage trees can be further constructed to reconstruct the evolutionary relationships among clones descended from a common ancestor.

（4）Precise UMI-based Quantification and Error Correction

The 12-nt UMI provides approximately 17 million molecular-tag combinations, systematically correcting PCR amplification bias and sequencing errors and preventing erroneous reads from being misinterpreted as novel clones or novel SHM sites—which would artificially inflate diversity.

（5）Optional Heavy- and Light-Chain Detection

Supports separate or simultaneous detection of IgH (heavy chain) and Igκ/Igλ (light chain). For native VH–VL pairing to directly clone functional antibodies, a single-cell BCR sequencing solution is available.

（6）Standardized Analysis Pipeline

A standardized pipeline has been established—from UMI deduplication and clonotype reconstruction (MiXCR/IgBLAST/IMGT) through isotype distribution, SHM analysis, clonal lineage construction, and visualization output—ensuring comparability across samples and batches. Raw FASTQ files are delivered in full.

Scope of application: This service uses RNA as the starting template and requires high-quality total RNA with RIN ≥ 7. It is not suitable for FFPE samples, pure gDNA, or severely degraded RNA. For gDNA or FFPE samples, a BCR multiplex PCR sequencing solution is recommended.

4. Applications

Antibody Drug Development: Mining candidate antibody variable-region (VH/VL) sequences from the full-length BCR repertoire, and screening high-affinity candidates by integrating SHM levels and affinity-maturation trajectories. For natively paired VH–VL sequences enabling direct cloning and expression, a single-cell BCR solution can be combined.

Vaccine Immunogenicity Research: Resolving antibody clonal expansion, isotype switching (e.g., IgM→IgG), and changes in SHM levels before and after vaccination, to quantitatively assess the magnitude, breadth, and maturity of the vaccine-induced humoral immune response.

Autoimmunity and Infectious Immunity: Identifying and tracking pathogenic autoreactive B-cell clones or protective neutralizing-antibody clones, and resolving disease-associated BCR motifs and public antibody clones.

B-cell Malignancy Clonality and Lineage Research: For clonality determination, tumor-of-origin clone identification, and clonal-evolution trajectory studies in B-cell malignancies such as multiple myeloma, B-ALL, CLL, and lymphoma (for research use).

Cell Therapy and Long-Term Follow-Up: For B-cell–targeting therapeutic products such as CAR-T, monitoring B-cell reconstitution dynamics, antibody-response recovery, and accompanying changes in clonal composition—supporting product characterization and long-term follow-up studies.

5. Report and Deliverables

The report covers the complete content from sequencing QC to systematic immune repertoire and antibody-feature analysis. Core analysis modules include:

·Sequencing data QC and UMI deduplication statistics (read quality, mapping rate, UMI distribution, effective molecule counts)

·Clonotype identification and quantification (UMI-corrected IgH/Igκ/Igλ clonotype tables and frequency distributions)

·Clonal diversity and clonality metrics (Shannon entropy, Simpson index, Chao1, Gini coefficient, etc.)

·V/D/J gene usage frequency analysis (IGHV/IGHD/IGHJ and light-chain frequencies, plus gene-pairing patterns)

·CDR3 sequence feature analysis (length distribution, amino acid composition, and sequence motifs)

·Antibody isotype distribution and class-switch analysis (IgM/IgG/IgA/IgD/IgE proportions and switching relationships)

·Somatic hypermutation (SHM) rate analysis (V-region mutation frequency, mutation-site distribution, and R/S ratio)

·Clonal lineage tree construction and clonally related (homologous) family analysis

·Top dominant clone ranking, complete clonotype sequence information, and inter-sample shared-clone analysis

·(Optional) Comparison against databases (IMGT, antibody databases), candidate antibody sequence screening, and customized visualization

Deliverables: An illustrated analysis report (PDF) + a detailed clonotype information table (Excel/CSV, including V/D/J gene annotation, CDR3 nucleotide/amino acid sequences, isotype annotation, SHM rate, UMI counts, and clonal frequencies) + raw sequencing data (FASTQ).

Figure 2. Schematic of BCR Antibody Isotype Distribution and Clonal Lineage Evolution

6. Service Workflow

7. Sample Requirements

*Note: RNA must be dissolved in nuclease-free water and must not contain poly(A) carrier; do not use heparin as an anticoagulant during blood collection; cells should be washed ≥ 2 times with Ca²⁺/Mg²⁺-free PBS, and fixed cells must not be used; avoid repeated freeze-thaw cycles, and submit 2–3× the required amount; ship frozen on dry ice throughout transport. Specific requirements are subject to the latest Sample Submission Form; please schedule and confirm the plan before shipping. This service is not suitable for FFPE samples, pure gDNA, or severely degraded RNA.

8. Technical Specifications

9. References

[1] U.S. Food and Drug Administration. Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment; Guidance for Industry. 2020.

[2] U.S. Food and Drug Administration. Considerations for the Development of CAR T Cell Products; Draft Guidance. 2024.

[3] U.S. Food and Drug Administration. Long-Term Follow-Up After Administration of Human Gene Therapy Products; Guidance for Industry. 2020.

[4] U.S. FDA De Novo Decision Summary DEN170080 (clonoSEQ Assay). 2018; supplemented 2020 (CLL indication).

[5] Scheijen B, et al. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS. Leukemia. 2019.

[6] Center for Drug Evaluation, National Medical Products Administration (NMPA). Technical Guidelines for the Pharmaceutical Research and Evaluation of Immune Cell Therapy Products (Trial). Announcement No. 30, 2022.